The potential pathophysiological role of tissue factor in age-related macular degeneration

Expert Review of Ophthalmology

Volumn 5, Issue 1, 2010, Pages 27-34

  Cho, Youngeun ^a   Rickles, Frederick R ^b   Parver, Leonard M ^c   Tuo, Jingsheng ^a   Chan, Chi Chao ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

age related macular degeneration; angiogenesis; apoptosis; inflammation; tissue factor

Indexed keywords

EID: 79953218983     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.09.58     Document Type: Article

References (63)

1. Friedman DS, O’Colmain BJ, Munoz B et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564–572 (2004).
2. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case–control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology 107, 2224–2232 (2000).
3. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, β carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 119, 1417–1436 (2001).
4. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 112, 533–539 (2005).
5. Evans JR, Fletcher AE, Wormald RP. 28,000 cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. Br. J. Ophthalmol. 89, 550–553 (2005).
6. Hyman L, Neborsky R. Risk factors for age-related macular degeneration: an update. Curr. Opin. Ophthalmol. 13, 171–175 (2002).
7. Tuo J, Bojanowski CM, Chan CC. Genetic factors of age-related macular degeneration. Prog. Retin. Eye Res. 23, 229–249 (2004).
8. Hughes AE, Orr N, Patterson C et al. Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking. PLoS Med. 4, e355 (2007).
9. Francis PJ, Schultz DW, Hamon S, Ott J, Weleber RG, Klein ML. Haplotypes in the complement factor H (CFH) gene: associations with drusen and advanced age-related macular degeneration. PLoS ONE 2, e1197 (2007).
10. Klein R. Overview of progress in the epidemiology of age-related macular degeneration. Ophthalmic Epidemiol. 14, 184–187 (2007).
11. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog. Retin. Eye Res. 28, 1–18 (2009).
12. Anderson DH, Talaga KC, Rivest AJ et al. Characterization of β amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp. Eye Res. 78, 243–256 (2004).
13. Crabb JW, Miyagi M, Gu X et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl Acad. Sci. USA 99, 14682–14687 (2002).
14. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp. Eye Res. 73, 887–896 (2001).
15. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 14, 835–846 (2000).
16. de Jong PT. Age-related macular degeneration. N. Engl. J. Med. 355, 1474–1485 (2006).
17. Coleman HR, Chan CC, Ferris FL III, Chew EY. Age-related macular degeneration. Lancet 372, 1835–1845 (2008).
18. Chu AJ. Role of tissue factor in thrombosis. Coagulation–inflammation–thrombosis circuit. Front. Biosci. 11, 256–271 (2006).
19. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler. Thromb. Vasc. Biol. 24, 1015–1022 (2004).
20. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am. J. Pathol. 134, 1087–1097 (1989).
21. Edwards RL, Rickles FR, Bobrove AM. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 54, 359–370 (1979).
22. Bluff JE, Brown NJ, Reed MW, Staton CA. Tissue factor, angiogenesis and tumour progression. Breast. Cancer Res. 10, 204 (2008).
23. Mackman N, Sawdey MS, Keeton MR, Loskutoff DJ. Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am. J. Pathol. 143, 76–84 (1993).
24. Muller I, Klocke A, Alex M et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 17, 476–478 (2003).
25. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 105, 2754–2770 (2005).
26. Engelmann B. Initiation of coagulation by tissue factor carriers in blood. Blood Cells Mol. Dis. 36, 188–190 (2006).
27. Chu AJ. Tissue factor mediates inflammation. Arch. Biochem. Biophys. 440, 123–132 (2005).
28. Pendurthi UR, Ghosh S, Mandal SK, Rao LVM. Tissue factor activation: is disulfide bond switching a regulatory mechanism? Blood 110, 3900–3908 (2007).
29. Ahamed J, Versteeg HH, Kerver M et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc. Natl Acad. Sci. USA 103, 13932–13937 (2006).
30. Chen J, Bierhaus A, Schiekofer S et al. Tissue factor – a receptor involved in the control of cellular properties, including angiogenesis. Thromb. Haemost. 86, 334–345 (2001).
31. Abe K, Shoji M, Chen J et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl Acad. Sci. USA 96, 8663–8668 (1999).
32. Zhang Y, Deng Y, Luther T et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J. Clin. Invest. 94, 1320–1327 (1994).
33. Belting M, Dorrell MI, Sandgren S et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat. Med. 10, 502–509 (2004).
34. Ahamed J, Ruf W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J. Biol. Chem. 279, 23038–23044 (2004).
35. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl Acad. Sci. USA 94, 663–668 (1997).
36. Chiarugi V, Ruggiero M, Magnelli L. Molecular polarity in endothelial cells and tumor-induced angiogenesis. Oncol. Res. 12, 1–4 (2000).
37. Chu AJ. Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem. Funct. 24, 173–192 (2006).
38. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc. Natl Acad. Sci. USA 98, 7742–7747 (2001).
39. Schoenmakers SH, Reitsma PH, Spek CA. Blood coagulation factors as inflammatory mediators. Blood Cells Mol. Dis. 34, 30–37 (2005).
40. Drake WT, Lopes NN, Fenton JW, Issekutz AC. Thrombin enhancement of interleukin-1 and tumor necrosis factor-α induced polymorphonuclear leukocyte migration. Lab. Invest. 67, 617–627 (1992).
41. Sower LE, Froelich CJ, Carney DH, Fenton JW, Klimpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for α-thrombin. J. Immunol. 155, 895–901 (1995).
42. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 99, 1053–1059 (2002).
43. Contrino J, Goralnick S, Qi J, Hair G, Rickles FR, Kreutzer DL. Fibrin induction of tissue factor in human vascular endothelial cells. Circ. 96, 605–613 (1997).
44. Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC. Antiapoptotic effect of coagulation Factor VIIa. Blood 102, 1708–1715 (2003).
45. Jiang X, Guo YL, Bromberg ME. Formation of tissue factor–Factor VIIa–Factor Xa complex prevents apoptosis in human breast cancer cells. Thromb. Haemost. 96, 196–201 (2006).
46. XL production. Circ. Res. 94, 1032–1040 (2004).
47. Cohen LH, Noell WK. Relationships between visual function and metabolism. In: Biochemistry of the Retina. Graymore CN (Ed.). Academic Press, NY, USA, 36–49 (1965).
48. Young RW, Bok D. Participation of the retinal pigment epithelium in the rod outer segment renewal process. J. Cell. Biol. 42, 392–403 (1969).
49. Wilson TM, Strang R, Wallace J, Horton PW, Johnson NF. The measurement of the choroidal blood flow in the rabbit using 85-krypton. Exp. Eye Res. 16 (6), 421–425 (1973).
50. Metelitsina TI, Grunwald JE, DuPont JC, Ying GS, Brucker AJ, Dunaief JL. Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 49 (1), 358–363 (2008).
51. Arjamaa O, Nikinmaa M, Salminen A, Kaarniranta K. Regulatory role of HIF-1α in the pathogenesis of age-related macular degeneration (AMD). Ageing Res. Rev. 8 (4), 349–358 (2009).
52. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye 23 (7), 1496–1508 (2009).
53. Sakamoto T, Ito S, Yoshikawa H et al. Tissue factor increases in the aqueous humor of proliferative diabetic retinopathy. Graefes. Arch. Clin. Exp. Ophthalmol. 239 (11), 865–871 (2001).
54. Topouzis F, Anastasopoulos E, Augood C et al. Association of diabetes with age-related macular degeneration in the EUREYE study. Br. J. Ophthalmol. 93 (8), 1037–1041 (2009).
55. Strukova S. Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis. Front. Biosci. 11, 59–80 (2006).
56. Grossniklaus HE, Ling JX, Wallace TM et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol. Vis. 8, 119–126 (2002).
57. Contrino J, Hair G, Reutzer DL, Rickles F. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat. Med. 2, 209–215 (1996).
58. Bora PS, Hu Z, Tezel TH et al. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc. Natl Acad. Sci. USA 100, 2679–2684 (2003).
59. Tezel TH, Bodek E, Sonmez K et al. Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of Factor VII-Fc chimeric antibody. Ocul. Immunol. Inflamm. 15, 3–10 (2007).
60. Redecha P, Tilley R, Tencati M et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 110, 2423–2431 (2007).
61. Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and Factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 94, 3413–3420 (1999).
62. Sivaprasad S, Bailey TA, Chong VN. Bruch’s membrane and the vascular intima: is there a common basis for age-related changes and disease? Clin. Experiment. Ophthalmol. 33, 518–523 (2005).
63. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin. Immunopathol. 30, 97–110 (2008).